Nexien Biopharma Inc
Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in … Read more
Nexien Biopharma Inc (NXEN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of March 2025: 0.029x
Based on the latest financial reports, Nexien Biopharma Inc (NXEN) has a cash flow conversion efficiency ratio of 0.029x as of March 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.02K) by net assets ($-450.52K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nexien Biopharma Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Nexien Biopharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Nexien Biopharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nexien Biopharma Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ORCO GERMANY - Dusseldorf Stock Exchang
DU:O5G
|
N/A |
|
Max Echo Technology Corp.
TWO:5228
|
N/A |
|
Traccom Inc
PINK:TRCC
|
N/A |
|
Mobile Streams Plc
LSE:MOS
|
-0.781x |
|
Penghua Shenzhen Energy Clean Energy Closed Infrastructure Securities Investment Fund
SHE:180401
|
N/A |
|
Blackstone / GSO Loan
LSE:BGLF
|
-0.001x |
|
SUNEVISION HLDGS
MU:VI6
|
N/A |
|
GRND3F
SA:GRND3F
|
N/A |
Annual Cash Flow Conversion Efficiency for Nexien Biopharma Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Nexien Biopharma Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-06-30 | $-361.25K | $-64.36K | 0.178x | -45.08% |
| 2023-06-30 | $-252.01K | $-81.75K | 0.324x | -49.23% |
| 2022-06-30 | $-117.61K | $-75.14K | 0.639x | -90.30% |
| 2021-06-30 | $-13.78K | $-90.75K | 6.588x | -71.59% |
| 2020-06-30 | $-6.37K | $-147.57K | 23.185x | +1058.25% |
| 2019-06-30 | $265.92K | $-643.38K | -2.419x | -227.13% |
| 2018-06-30 | $1.18 Million | $-875.34K | -0.740x | -221.62% |
| 2017-06-30 | $563.29K | $-129.53K | -0.230x | -- |